Women who developed a rash early in their treatment for HER2-positive breast cancer with lapatinib were more likely to go on to have pathologic complete response compared to those who did not get a rash, according to the results of an unplanned analysis of data from the NeoALTTO trial.
A new study shows that men who have a specific protein marker present in their prostate biopsy may benefit from close follow-up and additional biopsies as they may be at increased risk of developing cancer.
In this interview we discuss advances in whole-genome analyses, as well as novel blood-based assays in development to help diagnose and follow cancer patients through their treatment.
This breast cancer slide show features mammograms, ultrasound images, and CT scans of ductal carcinoma in situ, invasive ductal carcinoma, and other early-stage disease.
Tumor shrinkage is a valid indicator of response to VEGF inhibition among patients with metastatic renal cell carcinoma when evaluated by a single radiologist observer.
Concurrent administration of trastuzumab and anthracyclines resulted in a similar rate of pathologic complete response when compared to sequential administration in women with HER2-positive breast cancer, according to the results of a new study.
Following recent trial data showing an increased risk of dangerous blood clots with ponatinib, which led the FDA to request that the manufacturer stop marketing the drug, the FDA’s European counterpart has adjusted its recommendations for ponatinib but has not changed its “positive opinion” that led to the approval.
As part of our coverage for the 2013 American Society of Hematology Annual Meeting and Exposition, we discuss some of the research that will be highlighted during this year’s meeting.
The completion of a short web-based course improved the ability of primary care physicians to diagnose and manage benign and malignant skin cancer, according to the results of a new study.
